drugset / Trial / NCT02181998
A Trial on Efficacy and Safety of Full Dose Tenecteplase Combined With Unfractionated Heparin (UFH) or Enoxaparin in Acute Myocardial Infarction (AMI) in the Prehospital Setting
RandomizedParallel-groupOpen-labelTreatment
Summary
The primary objective of ASSENT 3 Plus (the same as for ASSENT 3) was to evaluate the safety and efficacy of full dose tenecteplase combined with unfractionated heparin (UFH, group A) and full dose tenecteplase combined with enoxaparin (ENOX, group B). An additional objective in ASSENT 3 Plus was to describe the different time intervals in the prehospital phase.
Timeline
- Start
- 2000-07
- Primary completion
- 2002-08
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Enoxaparin sodium | Other / unclassified | — | — |
| Subject | Tenecteplase | Protein / enzyme biologic | — | — |
| Comparator | Unfractioned Heparin | Unknown | — | — |